Loading...
XSTOALZ
Market cap26mUSD
Jan 13, Last price  
3.30SEK
1D
-2.38%
1Q
-6.29%
Jan 2017
-79.95%
IPO
-72.78%
Name

Alzinova AB

Chart & Performance

D1W1MN
XSTO:ALZ chart
P/E
—
P/S
1,089.80
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
30.03%
Rev. gr., 5y
-50.79%
Revenues
270k
-98.38%
2,189,961839,373954,334998,3875,252,9515,790,9629,360,0576,808,83714,898,03417,321,73816,633,432270,000
Net income
-16m
L+26.09%
-1,855,299-335,728-471,512-3,407,270-2,964,052-2,508,098-4,189,311-6,202,329-6,500,476-7,584,660-13,069,944-16,480,000
CFO
-15m
L+47.50%
00-715,192-3,209,590-2,764,089-2,130,802-3,967,356-3,975,735-6,265,728-9,819,766-10,313,736-15,213,000

Profile

Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.
URL
https://www.alzinova.com/
IPO date
Nov 25, 2015
Employees
4
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
270
-98.38%
16,633
-3.97%
Cost of revenue
(19,604)
(16,633)
Unusual Expense (Income)
NOPBT
19,874
33,267
NOPBT Margin
7,360.74%
200.00%
Operating Taxes
(18)
Tax Rate
NOPAT
19,874
33,285
Net income
(16,480)
26.09%
(13,070)
72.32%
Dividends
Dividend yield
Proceeds from repurchase of equity
26,284
36,860
BB yield
-21.34%
-54.61%
Debt
Debt current
Long-term debt
800
800
Deferred revenue
Other long-term liabilities
(800)
Net debt
(21,226)
(31,238)
Cash flow
Cash from operating activities
(15,213)
(10,314)
CAPEX
(16,633)
Cash from investing activities
(19,604)
(16,633)
Cash from financing activities
24,805
30,149
FCF
19,874
33,285
Balance
Cash
22,026
32,038
Long term investments
Excess cash
22,012
31,206
Stockholders' equity
(146,596)
(39,112)
Invested Capital
261,254
145,445
ROIC
9.77%
25.11%
ROCE
17.33%
31.29%
EV
Common stock shares outstanding
40,516
24,365
Price
3.04
9.75%
2.77
-56.99%
Market cap
123,169
82.50%
67,490
-40.55%
EV
101,943
36,253
EBITDA
19,874
33,267
EV/EBITDA
5.13
1.09
Interest
98
19
Interest/NOPBT
0.49%
0.06%